Protalix BioTherapeutics, Inc. (PLX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.9400 |
| Open | 1.9500 |
| Bid | 1.9800 x 1300 |
| Ask | 2.0600 x 2200 |
| Day's Range | 1.9350 - 2.0199 |
| 52 Week Range | 0.9400 - 2.2100 |
| Volume | |
| Avg. Volume | 993,168 |
| Market Cap | 100.825M |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2240 |
| Earnings Date | May 15, 2023 - May 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe Gout
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the first patient has been dosed in the Company's phase I First in Human (FIH) clinical trial of PRX-115, the Company's recombinant PEGylated uricase product candidate under development as a potential treat
- PR Newswire
Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature Bank
Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that it does not hold cash deposits or securities at either Silicon Valley Bank or Signature Bank, nor does it have any credit facility or other financial relationship with either institution. The Company maintain
- Insider Monkey
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2022 Earnings Call Transcript February 27, 2023 Operator: Good morning ladies and gentlemen and welcome to the Protalix full year 2022 earnings call. As a reminder, this conference is being recorded. I will now turn the conference over to your host, Monique Kosse of LifeSci Advisors, investor relations for Protalix. […]
